23andMe has appointed Jill Hagenkord to chief medical officer. Hagenkord joins 23andMe from InVitae where she served as medical director. Prior to that, she was chief medical officer and senior vice president at Complete Genomics. She was also founder and chief medical officer for iKaryos Diagnostics, associate professor of pathology at Creighton University School of Medicine, director of molecular pathology and clinical genomics at Creighton Medical Laboratories, and pathologist at Deltagen. She is a board-certified medical genetic pathologist.
Bio-Reference Laboratories has appointed Robert Daber to director of research and development and director of cancer genetics. Daber was previously the technical director of clinical genetics at the University of Pennsylvania, where he helped develop next-generation sequencing-based diagnostic cancer tests. Prior to that, he was a post-doctoral fellow at the Children's Hospital of Philadelphia.
Insilico Medicine, which is using genomics to discover new therapies targeted age-related diseases, has appointed cancer genomics expert Qingson Zhu to chief operating officer. Zhu spent seven years as a postdoctoral research fellow at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University where he worked on biomarker identification and drug development using microarray and next-generation sequencing technologies.